Avedro Inc Revenue Growth Rates (AVDR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Avedro Inc  (NASDAQ: AVDR)
 

AVDR's Revenue Growth by Quarter and Year

Avedro Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AVDR Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
4th Quarter December -
3rd Quarter September 11.05
2nd Quarter June 10.29
1st Quarter March 8.77
FY 30.11





AVDR Revenue third quarter 2019 Y/Y Growth Comment
Avedro Inc achieved in the third quarter 2019, above Company average Revenue rise of 75.33% year on year, to $ 11.05 millions.

Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 65 other companies have achieved higher Revenue growth. While Avedro Inc' s Revenue jump of 75.33% ranks overall at the positon no. 370 in the third quarter 2019.


AVDR Revenue ( Y/Y Growth %) 2019
 2018 2017 2016
4th Quarter December - - - -
3rd Quarter September 75.33 % - - -
2nd Quarter June 99.81 % - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Avedro Inc's third quarter 2019 Revenue $ 11.05 millions AVDR's Income Statement
Avedro Inc's third quarter 2018 Revenue $ 6.30 millions Quarterly AVDR's Income Statement


AVDR Revenue (Quarter on Quarter Growth %)

 2019
 2018 2017 2016
4th Quarter December - 27.3 % - -
3rd Quarter September 7.35 % 22.33 % - -
2nd Quarter June 17.33 % - - -
1st Quarter March 9.35 % - - -
FY (Year on Year)   - - - -


Back to AVDR Growth rate Comparisons >> Back to AVDR Growth rate Comparisons >>


Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #66
Healthcare Sector #118
Overall #370

Revenue Y/Y Growth Statistics
High Average Low
70.22 % 57.14 % 37.77 %
 
Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #66
Healthcare Sector #118
Overall #370
Revenue Y/Y Growth Statistics
High Average Low
70.22 % 57.14 % 37.77 %
 

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Avedro Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
17.28 % 12.32 % 7.36 %
(Jun 30 2019)  


AVDR's III. Quarter Q/Q Revenue Comment
Avedro Inc achieved in the III. Quarter 2019 below company average Revenue increase of 7.35% quarter on quarter, to $ 11.05 millions.

Within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Revenue quarter on quarter growth. While Avedro Inc's Revenue growth quarter on quarter, overall rank is 1106.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #209
Overall #1106
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #209
Overall #1106
Revenue Q/Q Growth Statistics
High Average Low
17.28 % 12.32 % 7.36 %
(Jun 30 2019)  


AVDR's III. Quarter Q/Q Revenue Comment
Avedro Inc achieved in the III. Quarter 2019 below company average Revenue increase of 7.35% quarter on quarter, to $ 11.05 millions.

Within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Revenue quarter on quarter growth. While Avedro Inc's Revenue growth quarter on quarter, overall rank is 1106.


Avedro Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Sep 30 2019 period, Avedro Inc's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Avedro Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Sep 30 2019 period, Avedro Inc's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Avedro Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AVDR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2019
Biocardia Inc 130.95%$ 130.952 millions
Igc Pharma Inc 124.54%$ 124.538 millions
United Cannabis Corp121.55%$ 121.551 millions
Cardiff Lexington Corporation120.75%$ 120.754 millions
Progyny Inc 120.15%$ 120.145 millions
Ultragenyx Pharmaceutical Inc 119.33%$ 119.332 millions
Cue Biopharma Inc 119.15%$ 119.154 millions
Healthlynked Corp117.29%$ 117.292 millions
Heron Therapeutics Inc 115.43%$ 115.425 millions
Biodelivery Sciences International Inc 114.09%$ 114.086 millions
Spark Therapeutics Inc 109.65%$ 109.648 millions
Apyx Medical Corp106.29%$ 106.291 millions
Lumos Pharma Inc 105.00%$ 105.000 millions
Tandem Diabetes Care Inc 104.60%$ 104.602 millions
Vaccinex Inc 104.04%$ 104.040 millions
Amarin Corp Plcuk103.18%$ 103.185 millions
Novan Inc 103.09%$ 103.086 millions
Ontrak Inc 102.45%$ 102.449 millions
Biocept Inc 100.80%$ 100.798 millions
Tivity Health Inc 100.64%$ 100.636 millions
Ironwood Pharmaceuticals inc 99.69%$ 99.688 millions
Arbutus Biopharma Corp92.88%$ 92.880 millions
Antares Pharma Inc 92.00%$ 91.997 millions
Precision Biosciences Inc91.46%$ 91.460 millions
Fortress Biotech Inc 88.90%$ 88.904 millions
Sanara Medtech Inc 85.73%$ 85.728 millions
Exact Sciences Corporation84.97%$ 84.972 millions
Cerus Corporation84.78%$ 84.785 millions
Pulse Biosciences Inc 84.75%$ 84.746 millions
Fulgent Genetics Inc 83.95%$ 83.947 millions


About Avedro Inc Revenue Growth Rates (AVDR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.